Expansion of High-Cost Medicines Available Through EOPYY Private Pharmacies – What Changes for Patients

The Hellenic National Organization for the Provision of Health Services (EOPYY) is expanding the list of new high-cost medicines available through private EOPYY pharmacies, facilitating patient access to high-cost treatments. The recent decision was published in the Government Gazette.

This development represents another step toward simplifying patient access to high-cost therapies, reducing the need for physical visits to EOPYY pharmacies.

The new regulation includes the addition of further medicines, broadening the scope of the measure. Among these are treatments for multiple sclerosis, such as the active substance ocrelizumab, as well as anticancer agents like imatinib and capecitabine, widely used in oncology. This expansion is expected to significantly benefit more patients, who until now had to be served through specific distribution points, often facing longer waiting times. Patients will gain convenience and improved continuity of care, as access to treatments becomes faster and more reliable.

The option to collect medicines from private EOPYY pharmacies is expected to substantially improve patients’ daily lives, reducing hassle and enhancing accessibility, especially for those with chronic or serious conditions. This change is also part of the broader digital transformation of health services, aiming for a more flexible and patient-centered system. Healthcare providers will be able to monitor medicine distribution more efficiently, ensuring timely support and guidance for patients throughout their treatment.

According to the Government Gazette:

The start date of the medicine distribution process, with supply by EOPYY and final delivery at the private pharmacy specified in ministerial decision EΑLE/GΠ/oικ.51724/19-11-2025, as listed in the table below, is set as the date when EOPYY’s upgraded electronic platform (fyk.eopyy.gov.gr) becomes fully operational for the submission of patient requests under the new procedure defined in the above ministerial decision.

You can read the Government Gazette here (greek text)

Read our previous articles on the HCM procedure here and here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

High Cost Medicines: One More Addition to Help Patients – Up to Three People Can Now Collect on Their Behalf

As of Monday, February 16, 2026, High-Cost Medicines for cancer patients can now be collected by up to three designated representatives, offering greater flexibility and easier access to treatment through community pharmacies.

This new possibility is particularly important for patients who require regular access to High Cost Medicines but may have difficulty getting to the pharmacy or live far from a pharmacy. By allowing representatives, care becomes more flexible and adapted to everyday needs, while ensuring the safety and correct use of the treatment. In this way, access to therapy is faster, more human-centered, and free from unnecessary hassle.

In this first phase, the option applies to patients with cancer and multiple sclerosis, and it will gradually extend to other High Cost Medicines categories. The steps for collection remain the same: the insured person logs into the platform using Taxisnet + AMKA, selects the pharmacy of their choice, and monitors the progress of their order.

For more details, see our previous article.

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Dispensing High-Cost Medicines (HCM) Through Private Pharmacies – What Changes for Patients

A recent Ministerial Decision (Government Gazette B’ 6333/27.11.2025) introduces significant changes to the distribution of High-Cost Medicines (HCM), allowing patients to receive these medicines not only from EOPYY pharmacies but also from private community pharmacies. This new framework replaces the 2020 regulation and aims to ease patient access, reduce inconvenience, and improve the delivery of essential therapies.

The list of HCM medicines included in this process is available in the corresponding Government Gazette here.

What Changes for Patients

  • The prescribing physician issues the prescription through the national e-prescription system (IDIKA).
  • Patients may choose to receive their medicine either from an EOPYY pharmacy or a private community pharmacy.
  • Through the dedicated HCM application (using Taxisnet credentials + AMKA), patients select the private pharmacy that will serve them.
  • Patients receive electronic notifications regarding the status of their order and the availability of the medicine for pickup.
  • Medicines are dispensed with zero patient co-payment.
  • The time from approval to pickup may not exceed 10 days.

What Changes for Private Pharmacies

Private pharmacists now assume an expanded role in handling High-Cost Medicines, with specific responsibilities and procedures.

  1. Medicine Receipt
  • The pharmacist scans the product’s barcode in the EOPYY system to complete the warehouse reconciliation process for EOPYY’s pharmaceutical depot.
  • The patient is automatically notified via the system once the medicine arrives at the pharmacy.
  1. Prescription Verification and Dispensing

The pharmacist must verify:

  • the patient’s identity or the presence of a valid authorization,
  • the accuracy of the prescription and its alignment with the prescribing physician’s instructions,
  • the correct medicinal product,
  • the presence of any required supporting documents,
  • the authenticity labels or deactivated safety features,
  • the physician’s signature and the recipient’s signature.

The pharmacist then signs and stamps the prescription to complete the dispensing process.

Failure to comply with these procedures may lead to sanctions under Presidential Decree 121/2008.

  1. Pharmacist Remuneration

For each dispensed HCM prescription, pharmacists receive:

  • a scientific service fee of €20.00 + VAT,

without the need to issue transport documents.

This cost is not included in the total pharmaceutical expenditure ceiling of EOPYY.

  1. Monthly Submission of Prescriptions

Every month, pharmacists must send:

  • the dispensed prescriptions,
  • the consolidated report,
  • and the service invoice
    to the EOPYY Department of Prescription Processing and Review.

Electronic images of prescriptions remain available for audit.

  1. Unexecuted Prescriptions

If a prescription is not executed:

  • the medicine is returned to the pharmaceutical company after 5 days,
  • and the company issues a credit invoice to EOPYY.
  1. Loss or Damage of Medicines

If the medicine is lost or damaged due to pharmacist responsibility,
EOPYY charges the pharmacist the procurement value of the product.

Why This Change Matters

The updated system:

  • reduces patient inconvenience,
  • relieves congestion in EOPYY pharmacies,
  • ensures faster access to essential therapies,
  • strengthens the role of community pharmacists,
  • and modernizes the distribution of High-Cost Medicines.

This development significantly improves the daily lives of patients who rely on regular access to specialized treatments — including many oncology patients. KAPA3 continues to stand by cancer patients and their families, offering reliable guidance and practical support so that every patient feels safe and fully informed about their rights and benefits.

Text/Adaptation: Ifiyenia Anastasiou for Kapa3